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1. Introduction 
Atrial fibrillation is the most common sustained cardiac arrhythmia, which is associated 
with a high risk of stroke and thromboembolism. The association of atrial fibrillation and 
valvular heart disease results in a substantial stroke and thromboembolic risk, with a 17-fold 
greater risk than unaffected controls (Wipf & Lipsky, 1990). 
Important insights into the pathophysiology of thrombus formation (thrombogenesis) in 
atrial fibrillation can be made by reference to the different components of Virchow’s triad 
for thrombogenesis, that is, abnormal blood flow, abnormal blood constituents and  vessel 
wall abnormalities (Brotman et al., 2004). 
There have been many studies which have focused on risk factors for thrombogenesis in 
atrial fibrillation . However, the studies exploring the presence of a hypercoagulable state in 
atrial fibrillation (Lip1995; Lip et al., 1995) have concentrated on various clotting factors, and 
markers of endothelial damage or dysfunction, rather than on platelets per se. In this 
chapter, we present an overview of the thrombogenic role of platelets in valvular atrial 
fibrillation. 
2. The platelet physiology 
2.1 The platelet structure 
Platelets were recognized as a distinct blood element in the late 19th century (and not white 
blood cells) (Bizzozero, 1882). Platelets are anucleated cells arising from cytoplasmic 
fragmentation of megakaryocytes in the bone marrow, and have a typical diameter of ~2–3 
μm. Platelets circulate in a discoid form and their average lifespan in humans is ~10 days 
(Hanson & Slichter, 1985). However, following activation, they undergo dramatic changes in 
shape and ultrastructure; the membranes become ruffled with cytoplasmic projections and 
the granules are centralized and discharged (Spaet, 1974; White, 2008). Normal human 
platelet count is ~150,000–400,000/μl, though spontaneous bleeding resulting from reduced 
(but functionally normal) platelets is unusual at levels >10,000/μl (Slichter, 2004). 
Despite their lack of a nucleus, platelets are actively involved in a broad range of 
physiologic and pathologic processes. Platelets contain a variety of mediators that regulate 
hemostasis and thrombosis as well as a myriad of other functions including recruitment of 
other cells (chemotaxis), vasomotor function, cell growth, and inflammation, among others. 
Relevant constituents for thrombosis are present both on the cell membrane and in the 
cytoplasm, mainly within platelet granules. The platelet membrane, which consists of a 
www.intechopen.com
 
Atrial Fibrillation - Basic Research and Clinical Applications 
 
64
typical bilayer of phospholipids, contains membrane glycoproteins that interact with 
various ligands, either soluble ligands that activate the platelets, or fixed ligands within the 
vessel wall or on other cells through which the platelets adhere to these structures. One 
unique feature of the platelet is that its plasma membrane contains a network of numerous 
invaginations into the platelet interior, connected to the exterior through small pores 
(White et al., 1999; White & Clawson, 1980), known as the open canalicular system (OCS). 
  
Dense granules Nucleotides 
  Adenine: ATP, ADP 
  Guanine: GTP, GDP 
Amines 
  Serotonin 
  Histamine 
Bivalent cations 
ǂ-granules Adhesion molecules 
   Platelet endothelial cell adhesion molecule-1 (PECAM- 1/CD31) 
   Fibrinogen 
   von Willebrand factor (vWF) 
   Thrombospondin-1 (TSP1) 
   Vitronectin, Fibronectin 
Mitogenic factors 
   Platelet-derived growth factor (PDGF) 
   Vascular endothelial growth factor (VEGF) 
   Transforming growth factor-ß (TGF-ß) 
Membrane proteins 
   P- selectin 
   CD40L 
   Glycoprotein IIb/IIIa (GPIIb/IIIa, aIIbß3 integrin, CD41/CD61) 
Coagulation factors 
   Fibrinogen, Plasminogen, Protein S, Kininogens 
   Factors V, VII, XI, XIII 
Protease inhibitors 
   C1 inhibitor 
   Plasminogen activator inhibitor-1 (PAI-1) 
   Tissue factor pathway inhibitor (TFPI) 
Matrix breakdown 
   Hydrolytic enzymes MMP - 2, MMP – 9 
Leucocyte recruitment 
   Chemokines: PF4, RANTES, ǃ- thromboglobulin, ENA-78, SDF - 1ǂ 
Lysosomes Glycosidases 
Proteases 
Cationic proteins 
Table 1. Contents of the three different granule subpopulations (ǂ-granules, dense granules, 
and lysosomes) of platelets (modified from Rendu & Brohard-Bohn, 2001).  
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This feature imparts upon the platelet a much greater surface area than would normally be 
found on such a small cell. Platelets contain a second channel system, derived from 
megakaryocyte smooth endoplasmic reticulum, known as the dense tubular system (DTS). 
The DTS stores calcium and a variety of enzymes involved in platelet activation; in contrast 
to the OCS, the DTS does not associate with the plasma membrane (Ebbeling et al., 1992; 
Rendu & Brohard-Bohn, 2001). Three main populations of platelet granules (alpha 
granules,dense granules,lysosomes) serve as secretory vesicles, releasing components to the 
extracellular fluid and also serve to direct molecules to the plasma membrane in a process of 
exocytosis (table 1) (Rumbaut & Thiagarajan, 2010). 
2.2 The platelet function 
Although platelets have an important role in the normal haemostatic response, they 
probably contribute to several diverse processes beyond hemostasis and thrombosis, 
including promoting inflammatory and immune responses, maintaining vascular integrity, 
and contributing to wound healing (Smyth et al., 2009). 
The contribution of platelets to hemostasis is different in arteries and veins. In the venous 
system, low-flow rates and stasis permit the accumulation of activated coagulation factors 
and the local generation of thrombin largely with a less prominent contribution from 
platelets. Venous thrombi contain platelets, but the dominant cellular component consists of 
trapped erythrocytes. In the arterial circulation, higher flow rates limit fibrin formation by 
washing out soluble clotting factors. Platelets, which work best at higher shear rates, help to 
form a physical barrier against further blood loss and, at the same time, provide a surface on 
which thrombin is generated and fibrin can accumulate (Brass, 2010).  
The formation of a stable platelet plug following vascular injury is often described as 
occurring in three distinct stages: (1) initiation, (2) extension, and (3) stabilization (Figure 1). 
Initiation by collagen fibrils (within the vessel wall which become exposed to the circulation 
when the endothelial cell monolayer is breached, forming a complex with von Willebrand 
factor (VWF) and glycoprotein (GP) Ib  on the platelet surface binds to the VWF A1 
domain)produces a platelet monolayer that supports the subsequent adhesion of activated 
platelets to each other. Extension occurs when additional platelets adhere to the initial 
monolayer and become activated. Thrombin, ADP, and thromboxane A2 (TxA2) play an 
important role in this step, activating platelets via cell surface receptors coupled to 
heterotrimeric G proteins. ADP is secreted from storage sites within platelet-dense granules. 
TxA2 is synthesized from arachidonic acid released from platelet membrane phospholipids 
when platelets are activated.TxA2 formation in platelets is dependent on cyclooxygenase-
1(COX-1). The local generation of thrombin is facilitated by activated platelets that provide a 
surface on which clotting factor complexes can be assembled once phosphatidylserine has 
moved to the platelet surface from the inner leaflet of the plasma membrane. Intracellular 
signaling downstream of agonist receptors activates integrin IIbǃ3 (GP IIb-IIIa), making 
cohesive interactions between platelets (ie, aggregation) via fibrinogen  possible 
.Stabilization refers to the later events of platelet plug formation that help to stabilize the 
platelet plug and prevent premature disaggregation, in part by amplifying signaling within 
the platelet. Examples include outside-in signaling through integrins and signaling through 
receptors whose ligands are located on the surface of adjacent platelets. The net result is a 
hemostatic plug comprised of activated platelets embedded within a cross-linked fibrin 
mesh, a structure stable enough to withstand the shear forces generated by flowing blood in 
arterial circulation (Brass, 2010). 
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Fig. 1. Stages in platelet plug formation. A classical model. (A) Prior to vascular injury, 
platelet activation is suppressed by endothelial cell-derived inhibitory factors. These include 
prostaglandin PGI2 (prostacyclin), nitric oxide (NO), and CD39, an ADPase on the surface of 
endothelial cells that can hydrolyze trace amounts of ADP that might otherwise cause 
inappropriate platelet activation. (B) Initiation. The development of the platelet plug is 
initiated by thrombin and by the collagen-VWF complex, which captures and activates 
moving platelets. Platelets adhere and spread, forming a monolayer. (C) Extension. The 
platelet plug is extended as additional platelets are activated via the release or secretion of 
TxA2, ADP, and other platelet agonists, most of which are ligands for G protein-coupled 
receptors on the platelet surface. Activated platelets stick to each other via bridges formed 
by the binding of fibrinogen, fibrin, or VWF to activated IIbǃ3. (D) Stabilization. Finally, 
close contacts between platelets in the growing hemostatic plug, along with a fibrin 
meshwork (shown in red), help to perpetuate and stabilize the platelet plug. This model is 
being revised as new observations (described in the text) of the behavior of individual 
platelets within the hemostatic plug add additional refinements (Brass, 2010 ,with 
permission).  
3. The assessment of platelet activation 
In general, the quantification of platelet abnormalities can be performed using a wide 
variety of measures, such as platelet volume, aggregometry (Gabassov et al., 1989), excretion 
of metabolites (FitzGerald et al., 1988), flow cytometry (Corash, 1990) to detect various 
platelet antigens, and by the measurement of increased plasma levels of platelet products, 
such as platelet factor 4, beta thromboglobulin (Chen &Wu, 1980; Ikeda et al.,1997) , the 
soluble adhesion molecule P-selectin (Blann et al., 1997),soluble CD40L(Choudhury et 
al.,2007) and matrix metalloproteinase-1(Martin et al.,2003) (Table 2). However, some 
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measures (such as platelet volume) are less useful or practical. Furthermore, the choice of 
method may depend on the nature of the study. For example, measurement of large 
numbers, say, in epidemiological studies may require the use of plasma markers rather than 
the more specialized, time-consuming techniques such as flow cytometry(Kamath et al., 
2001). 
 
1) Platelet aggregation in response to 
ADP 
Collagen 
Epinephrine 
Thrombin 
Thromboxane or arachidonic acid 
(2) Measurement of platelet release products  
In plasma: 
 Beta thromboglobulin 
Platelet factor 4 
Soluble P-selectin 
Soluble CD40L 
Matrix metalloproteinases 
 In urine: 
Thromboxane 
(3) Measurement of platelet surface antigens 
Flowcytometry: 
GP IIb/IIIa 
P selectin (CD63) 
Platelet microparticles 
CD40L 
Table 2. Assessment of platelet activation. 
4. The thrombogenesis in atrial fibrillation 
The association between atrial fibrillation and the risk of stroke and thromboembolism has 
long been recognized.  Approximately one  in three patients  with  atrial fibrillation not 
receiving anticoagulants will develop an ischemic stroke in their lifetime, with roughly two-
thirds being cardioembolic and one-third being atherothrombotic. Cardioembolic strokes are 
more disabling than atherothrombotic strokes, with a higher early mortality rate (Bejot et al., 
2009; Lip & Lim, 2007). 
Evidence suggests that the thrombogenic tendency in atrial fibrillation is related to several 
underlying pathophysiological mechanisms, which can be discussed in relation to Virchow’s 
triad for thrombogenesis (fig 2). Abnormal changes in flow are evident by stasis in the left 
atrium, and seen as spontaneous echocontrast. Abnormal changes in vessel walls—
essentially, anatomical and structural defects—include progressive atrial dilatation, 
endocardial denudation, and oedematous or fibroelastic infiltration of the extracellular 
matrix. Additionally, abnormal changes in blood constituents are well described, and 
include haemostatic and platelet activation, as well as inflammation and growth factor 
changes (Choudhury & Lip, 2004; Watson et al., 2009). These changes result in the  
prothrombotic or hypercoagulable state in this arrhythmia.  
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Fig. 2. Components of Virchow’s triad for thrombogenesis in atrial fibrillation Abnormal 
changes shown in the vessel wall (eg, atrial tissue changes, endothelial damage and 
dysfunction), in flow (stasis—eg, in the left atrial appendage), and in blood constituents (eg, 
haemoconcentration, platelets, coagulation cascade activation, inflammation), all factors 
contribute to propensity for thrombus formation (thrombogenesis) in atrial fibrillation. 
vWf=von Willebrand factor (Watson et al., 2009,with permission). 
An understanding of left atrial—left atrial appendage thrombogenesis may have its roots in 
distinguishing hemostatic and thrombotic clotting. Studies performed by Hoffman et al., 
2006 offer potential mechanistic insight and  their experimental findings suggest that a large 
volume of blood must flow over an injured surface, such as the left atrial—left atrial 
appendage endocardium in a person with atrial fibrillation for significant tissue factor, 
derived from both circulating cells and microparticles (George, 2008; Lechner & 
Weltermann, 2008), to accumulate in high concentrations. Furthermore,  hemostasis occurs 
rapidly, with tissue factor of local origin determining the rate of thrombus development 
.The cell-based model of coagulation translates well to left atrial-left atrial appendage 
thrombogenesis and supports a primary role for tissue factor-based thrombin generation, 
with a secondary role being played by platelets .While the results of clinical trials (Connolly 
et al., 2006; Healey et al., 2008) and meta-analyses are consistent with this hypothesis, 
several biological constructs potentially provide a mechanistic platform as well. 
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The integrated complexity of coagulation in general and platelet-dependent thrombin 
generation in particular is becoming evident. One of the most interesting and clinically 
relevant observations over the past decade is the concomitant interdependence and 
independence of platelet activation and thrombin generation. The former is best considered 
in the context of primary hemostasis and possibly arterial thrombosis-both highly 
dependent on platelet activation, platelet aggregation and thrombin generation (in 
concentrations sufficient to provoke further platelet activation).In the latter instance, platelet 
subpopulations with distinct intracellular calcium signaling properties yield procoagulant 
domains (Munnix et al., 2007) The down regulation of platelet aIIb/b3, in turn, attenuates 
proaggregatory potential. 
5. The role of platelets in valvular atrial fibrillation 
The risk of stroke and thromboembolism is a major complication of atrial fibrillation. The 
risk of thrombogenesis with atrial fibrillation increases over five-fold in the presence of 
rheumatic heart disease, especially mitral valve stenosis. Rheumatic heart disease is 
observed in 15% of Western   atrial fibrillation patients, but this is even a larger problem 
worldwide (Bejot et al., 2009). This increase in thrombogenic risk with valvular heart disease 
could in part explained by activation of platelets and the coagulation system. 
5.1 Mitral stenosis 
Platelet activation appears to play an important role in the initial step of thrombus 
formation in patients with rheumatic mitral stenosis (Kranidis et al., 1993). Evidence has 
been shown that shear stresses in turbulent flow occur as a result of stenotic valves induce 
platelet activation (Stein & Sabbah, 1976; Yu et al., 1978). 
Many studies have demonstrated that platelet activation, evaluated by measuring the 
secretory substance of platelets as beta- thromboglobulin (BTG) , Platelet factor 4 (PF4) and 
soluble P-selection, occurs in the peripheral blood of patients with rheumatic mitral stenosis 
and atrial fibrillation (Chen at al., 2004; Kataoka et al., 1994; Yetkin et al., 2003). 
Chen et al., 2003 demonstrated that in patients with moderate to severe mitral stenosis, 
increased regional left atrial platelet P-selection expression detected by flow cytometry had 
a significantly direct relationship with the severity of mitral stenosis. Also, they  found that 
the fraction of peripheral venous platelets expressing P-selection in patients with chronic 
lone atrial fibrillation did not differ from that of healthy volunteers who were in sinus 
rhythm and this result provided one possible basic mechanism to clarify the ineffectiveness 
of aspirin in preventing thromboembolism in patients with non valvular atrial fibrillation 
according to previous large clinical trials (Petersen et al., 1989; The Stroke Prevention in 
Atrial Fibrillation Investigatiors,1993).  
The role of the CD40-CD40L axis in patients with atherothrombotic diseases has generated 
interest as this molecule may play a pivotal link among platelets (Henn et al., 2001; Langer 
et al., 2005; Slupsky et al., 1998), inflammation ( Anand et al., 2003; Henn et al., 2001), the 
endothelium (Slupsky et al., 1998; Zhou et al., 1998), coagulation (Slupsky et al., 1998; Zhou 
et al., 1998) and, ultimately, thrombosis. The triad of functional activity of CD40L in 
atherosclerotic models, high content in platelets, and mobilization during platelet 
thrombosis provide a readily testable hypothesis and places platelet-derived CD40L as a 
possible important mitigating factor in atrial fibrillation.  In patients with moderate to 
severe mitral stenosis and atrial fibrillation, the plasma soluble CD40L levels were found to 
be higher than healthy controls or patients with lone atrial fibrillation (Chen et al., 2005). 
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Azzam & Zagloul, 2009 demonstrated that patients with rheumatic mitral stenosis and atrial 
fibrillation have enhanced platelet activation, assessed by elevated  platelet microparticles in 
the plasma which have a significantly direct relationship with the severity of mitral stenosis. 
Platelet microparticles are generated from activated platelets and may not only be a marker 
of platelet activation but also a pathophysiological mediator leading to thrombosis 
(Niuwland & Strurk, 2002). 
Correction of mitral stenosis by performing percutaneous transluminal mitral 
valvuloplasty (PTMV) not only confers significant beneficial haemodynamic effects but 
also seems to affect platelet activation. Yetkin et al., 2003 reported that soluble P-selection 
and BTG levels which are markers of platelet activation decreased significantly after 
PTMV, indicating a reduction in platelet activity. Zaki et al.,2000  also shown significant 
decrease in prethrombotic state 30 min. after PTMV by measuring BTG, PF4 in patients 
with a left atrial pressure <10mm HG after PTMV. Also, Chen et al., 2005 found that 
PTMV rapidly reduced platelet activity in patients with moderate-to-severe mitral 
stenosis, consequently rapidly reducing soluble CD40L released from platelets. On the 
contrary, Goldsmith et al., 2000a reported that increased levels of soluble P-selection 
immediately post procedure and at 24h, in association with increased venous von 
Willebrand factor levels at 24h after PTMV are in keeping with the increase in platelet 
activation and endothelial dysfunction following PTMV. These changes may contribute to 
the increased risk of thromboembolism following the procedure and suggest the need for 
adequate antiplatelet and anticoagulant therapy following PTMV. These studies therefore 
suggest that the degree of platelet activation corresponds inversely with the mitral valve 
orifice area and the more severe the mitral stenosis, the greater is the degree of platelet 
activation. Furthermore, damage or disease of the atrial wall, including endocrinal 
damage secondary to valve disease, may contribute to further thrombogenesis. 
5.2 Mitral valve  prolapse 
Mitral valve prolapse has been linked with systemic thromboembolism, especially in young   
women (Barnett et al., 1980), and transient   ischemic attacks or partial strokes occurring as a 
complication of mitral valve prolapse accounted for 40% of these cases in patients aged 
under 45 years .Mechanisms for this appear to be related to clot or platelet aggregates 
originating from the rough surface of prolapsed mitral valves or from the traumatized 
adjacent left atrial surface (Jeresaty, 1985). Indeed, thrombi have been found on the   leaflets 
of   patients with mitral valve prolapse who died of cerebral embolism (Lewis, 1988). There 
are also reports of shortened platelet survival and increased platelet coagulant activity in 
patients with cerebral embolism and mitral   valve prolapse (Lewis, 1988). 
On the other hand, recent population based and case-control studies demonstrated no 
increased frequency of   mitral valve prolapse among patients with stroke or transient 
ischemic attacks, including young patients (Gilon et al., 1999; Orenica et al., 1995; Petty et al., 
1994). In addition, patients with   mitral valve prolapse who had strokes were similar in age 
to the general stroke population, and many had other risk factors for strokes, including 
atrial fibrillation (Gilon etal., 1999; Nishimura et al., 1985; Orenica et al., 1995). Also, some 
studies on the platelets have failed to demonstrate an association of platelet activation with 
pure mitral valve prolapse alone (Tse et al., 1997), suggesting that if the predisposition of 
mitral valve prolapse to thromboembolism were true, it may well operate via a mechanism 
other than platelet activation alone. Perhaps the severity of mitral regurgitation in mitral 
valve prolapse may be a factor as reported by Martini et al., 1996 who studied the platelet 
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and coagulation activation in patients with mitral valve prolapse  and suggested that mitral 
valve prolapse  is not responsible per se for blood clotting activation, but in patients with 
severe mitral insufficiency an increase in thrombin generation can occur. These alterations in 
hemostatic system may represent a mechanism by which mitral regurgitation increases the 
risk of thromboembolic events in patients with mitral valve prolapse. 
5.3 Mitral regurgitation 
Mitral regurgitation appears to have variable effects on platelet activation and the risk of 
thromboembolism, which is dependent on the underlying status of the mitral valve and 
whether or not there is coexisting atrial fibrillation. Some studies have shown an increase in 
platelet activation in patients with severe mitral regurgitation (Tse et al., 1997) in association 
with mitral valve prolapse, when compared to patients with mitral valve prolapse and mild 
to moderate mitral regurgitation, which was independent of age and left atrial size. 
However, other studies failed to demonstrate the same effect (Martini et al., 1996), but 
instead report increased activation of the coagulation system and thrombin generation in 
these patients.  
For example, Karatasakis et al., 1995 showed that significant mitral  regurgitation correlates 
with a lower incidence of spontaneous echo contrast, thrombi and embolization in patients 
with rheumatic mitral valve disease. Similar studies by Hwaang et al., 1994 and Movsowitz 
et al., 1993 confirmed similar findings.  In patients with non-valvular atrial fibrillation, 
moderate to severe mitral regurgitation seems to protect against stroke especially in patients 
with left atrial enlargement (Nakagami et al., 1998). Also, Kranidis et al., 2000 demonstrated 
that mitral regurgitation  has a protective effect on the development of left atrial thrombus  
in patients with rheumatic valve disease and atrial fibrillation .Furthermore, the presence of 
mitral regurgitation appears to reduce intracardiac thrombus in patients with dilated  
cardiomyopathy (Maze et al., 1989).  
Nevertheless, there are limited data relating these clinical observations to the degree of 
platelet activation or thrombogenesis. However, Goldsmith et al., 2000b reported an 
intraoperative study of patients with severe mitral regurgitation, where soluble P-selectin 
levels (as an index of platelet activation) were significantly lower within the left atrium 
compared to peripheral vein levels, indicating reduced platelet activation in association with 
the ‘stirring’ effect of the (severe) mitral regurgitation jet.  
Does moderate to severe mitral regurgitation increase the risk of thromboembolism in mitral 
valve prolapse but paradoxically decrease the risk in rheumatic mitral valve disease and/or 
non-valvular atrial fibrillation? To answer this question, further studies are needed which 
would clarify the influence of mitral regurgitation on platelet activation in mitral valve 
prolapse, rheumatic mitral valve, and non-valvular atrial fibrillation.  
5.4 Aortic valve disease 
Haemodynamic studies have shown that diseased cardiac valves, whether stenosed or 
incompetent, create regions of increased turbulence and shear stresses that are large 
enough to damage the vascular endothelium and cellular blood elements, leading to 
abnormal haemorheology, platelet activation, and endothelial dysfunction (Stein & 
Sabbah, 1976). For example, the intensity of turbulence in patients with pure aortic 
stenosis  may be 10 times greater than normal while the intensity of turbulence in patients 
with pure aortic regurgitation  may be three times greater than normal (Stein & Sabbah, 
1976). 
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Goldsmith et al., 2000c measured plasma concentrations of soluble P-selectin  (a marker for 
platelet activation), von Willebrand  factor (a marker for endothelial cell dysfunction) and 
fibrinogen (as an index of haemorheology and a clotting factor), in 61 patients with 
moderate to severe aortic valve disease in sinus rhythm, and  reported  that patients with 
aortic valve disease had higher mean plasma fibrinogen, von Willebrand factor and soluble 
P-selectin levels, which were not significantly different between patients with aortic stenosis 
or regurgitation. 
Also, Prohaska et al., 2008 studied the platelet function in 660 patients considered for 
isolated coronary artery bypass graft (CABG) surgery, and in 421 patients considered for 
single aortic valve replacement (AVR). Platelet function was monitored preoperatively using 
the platelet function analyzer device (PFA-100), and  reported that due to disturbed flow 
and shear exposition  following an initial activation, the platelets are partially degranulated, 
shed microparticles, and might become involved in the pathogenesis of microvascular 
dysfunction and thrombotic events in patients with aortic valve disease. Furthermore  , 
Dimitrow et al., 2009 determined markers of thrombin generation (thrombin-antithrombin 
complex , prothrombin fragment 1+2 ), platelet activation (soluble CD40 ligand , beta-
thromboglobulin , P-selectin) in seventy-five patients with aortic stenosis, and reported that 
mean concentrations of thrombin and platelet markers were higher approximately two-fold 
in  patients than in controls and maximal gradient as an index of turbulent flow associated 
with activation of coagulation and platelets. 
6. The role of platelets in non- valvular atrial fibrillation 
Whilst abnormalities of clotting markers are well recognized in non-valvular atrial 
fibrillation, abnormal platelet activation has also been reported in these patients (Lip, 1995; 
Yamauchi et al., 1986). However, Kamath et al., 2002 found that platelet markers (plasma 
beta-thromboglobulin, soluble glycoprotein V) and coagulation markers (fibrin D-dimer) 
were higher in atrial fibrillation compared to healthy controls with no significant 
abnormalities of platelet aggregation in response to standard platelet agonists, again casting 
doubt on the extent and significance of platelet activation in atrial fibrillation- which they 
have previously reviewed (Kamath et al., 2001). Choudhury et al., 2008 assessed  platelet 
activation using 4 different aspects of platelet pathophysiology: 1) platelet surface 
expression of CD62P (P-selectin) and CD63 (a lysosomal glycoprotein) (by flow cytometry); 
2) mean platelet volume (MPV) (by flow cytometry); 3) plasma levels of soluble P-selectin 
(sP-selectin, enzyme-linked immunoadsorbent assay); and 4) total amount of P-selectin per 
platelet (pP-selectin) ("platelet lysis" assay). They concluded that there is a degree of excess 
of platelet activation in atrial fibrillation compared with "healthy control subjects," but no 
significant difference between atrial fibrillation patients and "disease control subjects" in 
sinus rhythm. Platelet activation may differ according to the subtype of atrial fibrillation, 
but this is not in excess of the underlying comorbidities that lead to atrial fibrillation. 
Platelet activation in atrial fibrillation may be due to underlying cardiovascular diseases, 
rather than due to atrial fibrillation per se. Also, Choudhury et al., 2007 suggested that there 
is an excess of platelet activation in AF patients compared to healthy control subjects, as 
measured by sCD40L and sP-selectin levels. However, there was no excess of platelet 
activation in atrial fibrillation patients compared to disease control subjects. This would 
support the argument that platelet activation in atrial fibrillation patients is more related to 
the associated vascular diseases than to the arrhythmia itself. Furthermore patients with 
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atrial fibrillation have been noted to have impaired matrix degradation, with abnormalities 
in matrix metalloproteinase-1 (MMP-1) and its inhibitor, tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1), although these again were not independently associated with 
the presence of atrial fibrillation on multivariate analysis (Marin et al., 2003). However, an 
independent relationship was noted between the MMP/TIMP system and the 
prothrombotic state (assessed by prothrombin fragments 1 and 2 levels). From the available 
data, it seems that increased interstitial fibrosis in atrial tissue is more likely due to 
underlying comorbidities, like hypertension, ischemic heart disease, or uncontrolled heart 
failure (circumstances associated with high risk to develop atrial fibrillation), rather than the 
presence of the arrhythmia itself.  
The heart rate does not seem to be related to the extent of platelet activation in atrial 
fibrillation (Yamauchi et al., 1986). Therefore, heart rate control therapy itself is unlikely to 
offer significant benefit in terms of reducing thromboembolic risk in atrial fibrillation. 
Nevertheless, exercise may increase platelet activation in atrial fibrillation (Furui et al., 
1987).  For example, Furui et al., 1987 report an increase in platelet sensitivity to ADP 
aggregation and the level of beta thromboglobulin in the plasma in 20 patients with lone 
atrial fibrillation in comparison with age-matched controls when exercising at up to 85% of 
predicted maximal heart rate. However, Li Saw Hee et al., 2001 did not demonstrate any 
significant increase in soluble P-selectin levels amongst patients with atrial fibrillation 
exercised to exhaustion. One reason for the difference in findings between the studies by 
Furui et al., 1987 and Li Saw Hee et al., 2001 may be the choice of  markers of platelet 
activation, and hence, different pathophysiological release mechanisms. Furthermore, there 
does not appear to be any significant diurnal variation in abnormal platelet activation in 
atrial fibrillation, as reflected by changes in soluble P-selectin levels (Li Saw Hee et al., 2000), 
but this may simply reflect the high thrombogenic state associated with chronic atrial 
fibrillation. 
The extent of platelet activation in non-valvular atrial fibrillation may be related to the other 
features of the left atrium. For example, an enlarged left atrium and reduced left atrial 
appendage flow velocity has been correlated with increased platelet ctivation by (Shinohara 
et al., 1998). The study by Shinohara et al., 1998 reported a significant difference in platelet 
activation amongst patients with nonvalvular atrial fibrillation with a low left atrial 
appendage velocity (<40 cm. s_1) when compared to patients with a high left atrial 
appendage velocity _40 cm. s_1. The patients with a low atrial appendage velocity also had 
a significantly higher prevalence of spontaneous echo contrast and left atrial thrombus, 
suggesting a relationship between platelet activation and pre-embolic events if atrial 
fibrillation was accompanied by abnormal flow dynamics within the left atrium. Using 
scanning electron microscopy, we have recently demonstrated atrial endocardial cell 
damage, which was most commonly seen in the left atrial appendage amongst patients with 
mitral valve disease and atrial fibrillation (Goldsmith et al., 2000d). The interaction between 
activated platelets or clotting factors and the damaged endocardium may in part contribute 
to thrombogenesis within the left atrium. 
Whether the peripheral venous levels of markers of platelet activation and thrombogenesis 
truly and wholly reflect left atrial levels of coagulation and platelet activation in non-
valvular atrial fibrillation is not exactly clear. Li Saw Hee et al., 1999 demonstrated that there 
was no significant difference in the markers of platelet activation and thrombogenesis 
between the atria and the periphery vein amongst patients with atrial fibrillation due to 
mitral stenosis . Peverill et al., 1996 found that the markers of coagulation activity in similar 
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patients were no different between the left atrium and the periphery in the absence of left 
atrial spontaneous echo contrast. However, levels were significantly raised in the left atrium 
when compared to the periphery in the presence of left atrial spontaneous echo contrast, 
irrespective of the underlying rhythm. Similarly, Yamamoto et al., 1995 demonstrated a 
significant difference in the levels of some markers of coagulation between the left atrium 
and the periphery, namely, thrombin–antithrombin III complex and fibrinopeptide A in 
patients with mitralstenosis, but failed to demonstrate the same with respect to another 
marker of platelet  activation, namely, beta-thromboglobulin. 
7. Platelet activation and thromboembolic risk in atrial fibrillation 
Perhaps a continuum exists between normal platelet function, ‘statistically’ abnormal 
platelet function and overt thrombosis in patients with cardiovascular disease and stroke. 
Thus the abnormal platelet activation in atrial fibrillation, as summarized in the evidence 
above, may represent a ‘pre-embolic’ status in non-valvular atrial fibrillation (Pongratz et 
al., 1997). Indeed, platelet activation seems to occur even before the occurrence of 
spontaneous echo contrast in patients with atrial fibrillation (Heppell et al., 1997) and is 
correlated with both spontaneous echo contrast (Pongratz et al., 1997) and left atrial 
thrombus (Heppell et al., 1997) in atrial fibrillation.  
For example, Pongratz et al., 1997 demonstrated that the amount of circulating platelets 
expressing P-selectin was significantly higher in the patients with spontaneous echo contrast 
or left atrial thrombus in comparison with patients without either of these, or healthy 
controls. The study by Heppell et al., 1997 reported that plasma levels of beta 
thromboglobulin were independently associated with left atrial thrombus whether or not 
spontaneous echo contrast was present. Studies in canine models have also demonstrated 
that platelet activation is significantly associated with silent cerebral infarction in atrial 
fibrillation (Minamino et al., 1998).  
However, other clinical studies have demonstrated platelet activation in atrial fibrillation 
but failed to relate the former to the risk of thromboembolism. Thus, even though platelet 
activation appears to be significantly correlated with spontaneous echo contrast and left 
atrial thrombus, it does not seem to be convincingly correlated with stroke (or transient 
ischaemic attack) in nonvalvular atrial fibrillation. For example, the study by Gustafsson et 
al., 1990 showed that patients with atrial fibrillation and stroke had no greater platelet 
activation than patients with atrial fibrillation without stroke, whilst patients with sinus 
rhythm and stroke had no greater platelet activation than controls in sinus rhythm without 
stroke; patients with non-valvular atrial fibrillation without stroke had significantly more 
platelet activation than individuals with stroke in sinus rhythm. Whether platelet activation 
contributes to stroke/transient ischaemic attack in atrial fibrillation is not clear, and whether 
it can be used as a predictor of risk of stroke in atrial fibrillation in addition to other 
parameters, such as hypertension and left ventricular dysfunction still needs to be clarified.  
Thus, the available evidence suggests that thromboembolism in atrial fibrillation is probably 
due to enhancement of various components of the coagulation system due to stasis of blood 
in the inordinate and irregular atria, rather than to platelet activation per se (Nagao et al., 
1995). The relative role of coagulation versus platelet activation in the pathogenesis of 
thrombogenesis in patients with atrial fibrillation can roughly be inferred from the results of 
antithrombotic drug interventions that have been tested in randomized clinical trials. 
Among non-vavular atrial fibrillation patients, the relative risk reduction (RRR) for stroke 
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that is achieved with moderate intensity oral anticoagulant [international normalized ratio 
(INR)=2-3] compared to placebo is approximately 65%, as opposed to the 20% RRR achieved 
with aspirin versus placebo (Hart et al., 2007; Lip & Lim, 2007). Consistently, moderate 
intensity oral anticoagulant produces a RRR for stroke of 40% compared to aspirin, and of 
30% compared to aspirin +clopidogrel (Hart et al., 2007). Interestingly, among medium-high 
risk non-valvular AF patients not eligible to make warfarin, aspirin+ clopidogrel was 
superior to aspirin alone for stroke prevention (Connolly et al., 2009). 
Taken together, these results indicate that inhibition of coagulation remains the mainstay in 
preventing   atrial fibrillation –related thrombogenesis. The lesser but significant role of 
platelets- best inhibited by a combined antiplatelet drug regimen – is presumably related to 
the prominent involvement of platelets in the pathogenesis of atherothrombotic (that is, 
non-cardiombolic) events (Lip et al., 2009).  
8. Conclusion 
The thrombogenic role of platelets in atrial fibrillation is clearly complex and remain partly 
understood. Definitive answers to the questions of whether platelet activation contribute 
towards stroke in atrial fibrillation or is it just an associated factor? Does a reduction   in 
platelet   activation beneficially influence thromboembolic risk in atrial fibrillation? are far 
from simple and compare with the somewhat equivocal  benefits of antiplatelet drugs  in 
atrial fibrillation in clinical trials. Future directions in this field should involve further 
clarification of the role of different aspects of platelet activation in atrial fibrillation. 
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